EUVIMEDEUVIMED entdecken
Crossref

Recombinant human holo-lactoferrin in complex with oleic acid suppresses the growth of solid myeloma more efficiently than its apo-form

A Yu Elizarova, A V Sokolov iD, V A Kostevich, N P Gorbunov iD, I V Kudryavtsev, Yu M Berson, V N Yermalitsky, A I Budevich, V B Vasilyev iD

Biochemistry and Cell Biology · 2025

DOI: 10.1139/bcb-2024-0159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2025. Verfasst von A Yu Elizarova und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Medicine, Saint-Petersburg, Russia. Hauptthemen laut MEDLINE: Lactoferrin, Oleic Acid, Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: State Assignment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our previous study showed antitumor activity of the complex formed by iron-free recombinant human lactoferrin (apo-recHLF) and oleic acid (OA) (1:8 molar ratio) in a model of murine hepatoma 22a inoculated to C3HA mice. Taken alone, apo-recHLF was less efficient; i.e., the tumor growth index was 0.14 for recHLF-8OA and 0.63 for recHLF as compared with 1.0 in the control animals. In the present study, we evaluated antitumor activity of iron-saturated recHLF per se and of the complexes formed by OA with apo-recHLF and holo-recHLF. Balb/c mice with solid myeloma Sp2/0 were subjected to the 10-day treatment with daily intraperitoneal (i/p) injections of 10 mg iron-saturated recHLF with OA (1:8) per animal (0.4 g/kg). In 15 days, the tumor growth was substantially inhibited. Mean tumor mass was 93% lower as compared with the control value ( p < 0.01). I/p injections of apo-recHLF/OA complex did not inhibit the tumor growth. Holo-recHLF used without OA had less pronounced antitumor effect as compared with their complex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactoferrinOleic AcidMultiple MyelomaAntineoplastic AgentsAnimalsMiceHumansMice, Inbred BALB CRecombinant ProteinsCell Line, TumorCell ProliferationApoproteinsFemale

Stichwörter der Autor:innen

antitumor effectin vivo studyironlactoferrinoleic acidsolid tumors

Substanzen

LactoferrinOleic AcidRecombinant ProteinsAntineoplastic AgentsApoproteins

Autor:innen und Institutionen

  • Institute of Experimental Medicine, Saint-Petersburg, Russia.
  • Saint-Petersburg State University, Saint-Petersburg, Russia.
  • Scientific Practical Center of Animal Breeding, Zhodino, Belorussia.

ORCID-Profile: A V Sokolov, N P Gorbunov, V B Vasilyev

Förderung

  • State Assignment

Zitieren

APA

Elizarova, A., Sokolov, A. V., Kostevich, V., Gorbunov, N., Kudryavtsev, I., Berson, Y., Yermalitsky, V., Budevich, A., & Vasilyev, V. (2025). Recombinant human holo-lactoferrin in complex with oleic acid suppresses the growth of solid myeloma more efficiently than its apo-form. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2024-0159

Vancouver

Elizarova A, Sokolov AV, Kostevich V, Gorbunov N, Kudryavtsev I, Berson Y, et al. Recombinant human holo-lactoferrin in complex with oleic acid suppresses the growth of solid myeloma more efficiently than its apo-form. Biochemistry and Cell Biology. 2025. doi:10.1139/bcb-2024-0159

BibTeX
@article{Elizarova2025,
  author = {Elizarova, A Yu and Sokolov, A V and Kostevich, V A and Gorbunov, N P and Kudryavtsev, I V and Berson, Yu M and Yermalitsky, V N and Budevich, A I and Vasilyev, V B},
  title = {Recombinant human holo-lactoferrin in complex with oleic acid suppresses the growth of solid myeloma more efficiently than its apo-form},
  journal = {Biochemistry and Cell Biology},
  year = {2025},
  doi = {10.1139/bcb-2024-0159}
}
Kostenlos starten →